{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-005020","form_type":"8-K","ticker":"KRRO","cik":"0001703647","company_name":"Korro Bio, Inc.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.503976+00:00","generated_at":"2026-05-28T03:33:17.385844+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Korro Bio dosed first participants in Phase 1/2a study of KRRO-110 for AATD; interim data H2 2025","bullets":["First participants dosed in REWRITE Phase 1/2a study of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD).","Interim data from Part 1 (single ascending doses) expected H2 2025; study completion anticipated in 2026.","Pipeline update: Korro targets 3 candidates, 2 tissue types, single platform (3-2-1 strategy) by 2027.","Novo Nordisk partnered program in cardiometabolic indication progressing towards clinic."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-005020","json":"https://secwatch.observer/filing/0001193125-25-005020.json","markdown":"https://secwatch.observer/filing/0001193125-25-005020.md","text":"https://secwatch.observer/filing/0001193125-25-005020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703647/000119312525005020/0001193125-25-005020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703647/000119312525005020/d915237d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T03:33:17.385844+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}